In a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...

Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...

Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...

Aurobindo Pharma's China facility is set to achieve break-even by the end of fiscal year 2026. The company anticipates significant growth d...

Largest Indian pharma M&A in final lap; PE firm GTCR only other contender. A portfolio company of Advent International, Zentiva will signif...

The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett...

A Bloomberg report said two executives of Heritage Pharma – the US arm of Indian drug maker Emcure - are preparing to plead guilty to price...

People close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.

"When you see how much the prices of these drugs have increased just over the past year, it's staggering, and we want to know why," said Cu...